MJsAngelOfMusic
Premium Member
Last edited:
Latest on MJJC
- Latest Michael Jackson News
- Click Here to Join Our Community
- Follow us on X
- Wanna talk Michael? Come join the chat rooms
- The Michael Jackson Chart Watch
- Become an MJJC Patron
- Join the Premium Member Group and Get Lot's of Extra's
- Major Love Prayer - Worldwide Monthly Prayer Every 25th
- MJJC Exclusive Q&A - We talk to the family and those in and around Michael
- Join us in the Chat Rooms
- Find us on Facebook
DIET PILLS - Xenadrine EFX
- Thread starter twinklEE
- Start date
Well, I weigh 145lbs and am about 5'3, I wanna loose 10lbs, I don't think it's enough for my skin to become saggy?.
Last edited:
Thanks girl I'm going to write u a pm later today :flowers:
Nirvana
Proud Member
Thanks duranduran and mjsangel for answering my question
MJsAngelOfMusic
Premium Member
oh girl! that's not bad! Also, if you are going by the BMI chart be very careful. But yes, loosing just 10 pounds will bring you down to a normal BMI. But do you do any sports? My BMI is slightly higher cause I weight train..so I have more lean muscle but I don't look my size! lol. But I'm still in the normal range too. And def not enough to make you saggy but still lose the 10 pounds the right way to keep it off.:cheeky:
callmerose
Proud Member
- Joined
- Jul 25, 2011
- Messages
- 918
- Points
- 0
This is from the Federal Trade Commision web site. Link at the end. I wouldn't waste my money if I were you.
"TC Concludes Case Against Marketers of Xenadrine EFX; Court Ruling Requires Final Defendant to Accept Settlement Terms
The Federal Trade Commission’s case against the marketers of Xenadrine EFX, a purported weight-loss product, has ended, with the final defendant in the case settling charges of false and unsubstantiated advertising. The marketers claimed that Xenadrine EFX was clinically proven to cause rapid and substantial weight loss and was more effective than ephedrine-based diet products, and their ads included consumer testimonials.
In 2005, the FTC charged defendant Tracy Chinery, her husband Robert Chinery, Jr., and one of their companies, RTC Research & Development, LLC, with making false and unsubstantiated weight-loss claims for Xenadrine EFX. In 2006, the U.S. District Court for the District of New Jersey entered a settlement agreement between the FTC and two of the three defendants – Robert Chinery and RTC – that prohibited such conduct and provided for consumer redress.
The parties agreed that the only remaining issue was whether Tracy Chinery’s conduct as the managing member of RTC and as an officer and employee of Nutraquest, Inc., the original marketer of Xenadrine EFX, was sufficient to find her personally liable for the advertising under the FTC Act. The parties stipulated to an expedited procedure under which Tracy Chinery would sign a settlement agreement that was virtually identical to the one signed by Robert Chinery and RTC unless the court rejected the Commission’s claims against Tracy Chinery by granting either a motion to dismiss or a motion for summary judgment in her favor.
The court denied Tracy Chinery’s motion to dismiss in July 2007, ordered discovery to proceed, and then denied her motion for summary judgment in March 2009. Tracy Chinery signed the settlement agreement, which the court has now entered.
Under the final order, all three defendants are barred from making any claims about the health benefits, performance, efficacy, safety, or side effects of any weight-loss product, dietary
supplement, food, drug, or device, unless the representation is true, not misleading, and substantiated by competent and reliable scientific evidence. The order also prohibits
misrepresentations about any test or study, and about the actual experience of any user or endorser. Finally, it requires clear and prominent disclosure of any relationship that would materially affect the weight or credibility given to a testimonial or endorsement provided by a user of the product.
Under the 2006 settlement, the defendants, including Tracy Chinery’s company, RTC, paid $8 million for consumer redress and agreed to limit their future advertising claims. The new settlement with Tracy Chinery does not require her to make any monetary payments beyond"
http://www.ftc.gov/opa/2009/04/xenadrine.shtm
"TC Concludes Case Against Marketers of Xenadrine EFX; Court Ruling Requires Final Defendant to Accept Settlement Terms
The Federal Trade Commission’s case against the marketers of Xenadrine EFX, a purported weight-loss product, has ended, with the final defendant in the case settling charges of false and unsubstantiated advertising. The marketers claimed that Xenadrine EFX was clinically proven to cause rapid and substantial weight loss and was more effective than ephedrine-based diet products, and their ads included consumer testimonials.
In 2005, the FTC charged defendant Tracy Chinery, her husband Robert Chinery, Jr., and one of their companies, RTC Research & Development, LLC, with making false and unsubstantiated weight-loss claims for Xenadrine EFX. In 2006, the U.S. District Court for the District of New Jersey entered a settlement agreement between the FTC and two of the three defendants – Robert Chinery and RTC – that prohibited such conduct and provided for consumer redress.
The parties agreed that the only remaining issue was whether Tracy Chinery’s conduct as the managing member of RTC and as an officer and employee of Nutraquest, Inc., the original marketer of Xenadrine EFX, was sufficient to find her personally liable for the advertising under the FTC Act. The parties stipulated to an expedited procedure under which Tracy Chinery would sign a settlement agreement that was virtually identical to the one signed by Robert Chinery and RTC unless the court rejected the Commission’s claims against Tracy Chinery by granting either a motion to dismiss or a motion for summary judgment in her favor.
The court denied Tracy Chinery’s motion to dismiss in July 2007, ordered discovery to proceed, and then denied her motion for summary judgment in March 2009. Tracy Chinery signed the settlement agreement, which the court has now entered.
Under the final order, all three defendants are barred from making any claims about the health benefits, performance, efficacy, safety, or side effects of any weight-loss product, dietary
supplement, food, drug, or device, unless the representation is true, not misleading, and substantiated by competent and reliable scientific evidence. The order also prohibits
misrepresentations about any test or study, and about the actual experience of any user or endorser. Finally, it requires clear and prominent disclosure of any relationship that would materially affect the weight or credibility given to a testimonial or endorsement provided by a user of the product.
Under the 2006 settlement, the defendants, including Tracy Chinery’s company, RTC, paid $8 million for consumer redress and agreed to limit their future advertising claims. The new settlement with Tracy Chinery does not require her to make any monetary payments beyond"
http://www.ftc.gov/opa/2009/04/xenadrine.shtm